Pearl Therapeutics, a biopharmaceutical company, has upped its first round of funding to $33.5 million after an additional $18 million investment, according to VentureWire.
New investor Nektar Therapeutics joins all of the company's previous investors including Clarus Ventures, New Leaf Ventures and 5AM Ventures in this raise.
The Redwood City, Calif.-based Pearl Thera now has $36.4 million including debt funding.